Company profile
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LOTILANER | approved | — | 2 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05387083 | phase2 | completed | 2022-12-12 | 2024-06-26 | Tarsus Pharmaceuticals, Inc. | A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 |
| NCT05138796 | phase1 | completed | 2021-05-06 | 2022-03-25 | Tarsus Pharmaceuticals, Inc. | A Pharmacokinetic Study of TP-05 in Healthy Subjects |
| NCT05138861 | phase1 | completed | 2021-02-09 | 2021-09-03 | Tarsus Pharmaceuticals, Inc. | A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects |
| NCT07562087 | phase2 | active_not_recruiting | 2026-03-09 | 2027-10-01 | Tarsus Pharmaceuticals, Inc. | A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure |
| NCT06054217 | phase2 | unknown | 2023-08-01 | 2024-06-15 | Tarsus Pharmaceuticals, Inc. | Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 217603 | NDA | TARSUS PHARMACEUTICALS INC | ||||
Loading… | ||||||